Intraductal Papillary Mucinous Neoplasm (IPMN) Database - A Tool to Predict Pancreatic Cancer
Recruiting · NCT05117723 · Observational (researchers observe without assigning treatment) · Lead sponsor: St Vincent's Hospital Melbourne
View the official record on ClinicalTrials.gov →What this trial is about
Pancreatic cancer is the 5th leading cause of cancer death in Australia. Surgery remains the most effective treatment for early pancreatic cancer and currently the only potential for cure. Unfortunately, many patients present with advanced disease and are not suitable for surgery. Therefore, it is vital to detect these cancers early. In the absence of significant data from prospective studies, all of the guidelines are based on a critical review of available data and consensus of experts. The primary aim is to delineate the progression of IPMN to pancreatic malignancy as confirmed by surgical pathology, radiology and biochemical diagnosis. The secondary aims are (i) To outline the management of IPMNs for those who have progressed straight to surgery or surveillance by endoscopic ultrasound (EUS) (ii)To validate the International consensus guidelines for management of IPMN - Fukuoka consensus guidelines and tertiary aim to identify potential risk factors, if any that increase risk of malignancy within the IPMNs.
Who can take part
Inclusion criteria
- Adult patients between the age of 18 and 90 years old who have been identified with a cystic mass consistent with IPMN on imaging
Exclusion criteria
- Patients who formally decline enrolment into the study
Where it is running
1 location listed.
- St Vincent's Hospital Melbourne - Fitzroy, Victoria, Australia